Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | STK4 | Q13043 | 8/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 4/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633514 | 1.00 | CDK1 (0.44) | CDK1CDK2CDK9STK4FGFR4 | |
| SCHEMBL1633356 | 1.00 | CDK1 (0.44) | CDK1CDK2CDK9STK4FGFR4 | |
| SCHEMBL1633835 | 0.83 | IKBKB (0.47) | CDK1CDK2CDK9STK4PTK2 | |
| SCHEMBL1633031 | 0.82 | FGFR4 (0.47) | CDK1CDK2CDK9STK4FGFR4 | |
| SCHEMBL1633709 | 0.82 | SYK (0.47) | CDK1CDK2CDK9STK4JAK2 | |
| SCHEMBL1632397 | 0.81 | TBK1 (0.57) | CDK1CDK2CDK9JAK2PTK2 | |
| SCHEMBL1632154 | 0.80 | CDK2 (0.46) | CDK1CDK2CDK9STK4PTK2 | |
| SCHEMBL1633194 | 0.80 | CDK1 (0.48) | CDK1CDK2CDK9STK4FGFR4 | |
| SCHEMBL1632614 | 0.80 | CDK1 (0.48) | CDK1CDK2CDK9STK4FGFR4 | |
| SCHEMBL1632609 | 0.80 | CDK1 (0.48) | CDK1CDK2CDK9STK4FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | CDK1 83/4885CDK2 29/4885CDK9 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.